Galera Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
GRTX Nasdaq 8731 https://www.galeratx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Galera Therapeutics Inc

Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates - Nov 14th, 2023 12:00 pm
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update - Oct 31st, 2023 11:00 am
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem - Sep 18th, 2023 11:00 am
Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference - Sep 5th, 2023 11:00 am
All You Need to Know About Galera Therapeutics, Inc. (GRTX) Rating Upgrade to Buy - Aug 18th, 2023 4:00 pm
Chevron upgraded, SolarEdge downgraded: Wall Street's top analyst calls - Aug 16th, 2023 2:00 pm
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates - Aug 14th, 2023 11:00 am
Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News - Aug 11th, 2023 2:34 pm
Galera shares plunge 85% on FDA rejection; workforce cut by more than half - Aug 10th, 2023 2:12 pm
Galera shares tank after US FDA declines to approve inflammation disease drug - Aug 9th, 2023 10:30 pm
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese - Aug 9th, 2023 8:31 pm
Despite Galera Therapeutics' Pullback, Insiders Still Gained US$102k - Jun 28th, 2023 12:11 pm
Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting - Jun 5th, 2023 6:15 pm
Galera Therapeutics, Inc.'s (NASDAQ:GRTX) largest shareholders are retail investors with 45% ownership, institutions own 34% - May 18th, 2023 12:45 pm
Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer - May 18th, 2023 12:00 pm
Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates - May 11th, 2023 11:00 am
Galera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 4th, 2023 8:01 pm
Galera Expands Commercial Leadership Team - May 1st, 2023 11:00 am
Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting - Apr 26th, 2023 2:00 pm
Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology - Mar 10th, 2023 12:00 pm